Reducing Cost of Azythromycin by Transferring From IV to Oral Therapy

Not Applicable

Withdrawn

• Conditions: Pneumonia
• Interventions: Behavioral: education

• Registration Number: NCT01741909
• Lead Sponsor: HaEmek Medical Center, Israel

Brief Summary

Intravenous Azythromycin therapy is considerably more expensive than oral therapy. The investigators believe that intravenous therapy is prolonged more that necessary and that oral therapy can be used much earlier in the course of the disease. The investigators plan to check if that statement is true and intervene in order to shorten the intravenous therapy.

Detailed Description

The study will be performed in two stages. First a retrospective review of medical files of 50 patients hospitalized in the Haemek Medical Center with severe community acquired pneumonia, treated with azythromycin. The files will be reviewed for the criteria clinical improvement, and for azythromycin therapy, oral or intravenous.

The results of this review will help us define the appropriate behavioral intervention in order to cause doctors to transfer from IV to PO therapy at the earliest appropriate time. An intervention such as posters, pharmacy overseeing etc will be introduced. 3 months after the intervention, an additional 50 files of pneumonia patients treated with azythromycin will be reviewed in order to check the efficacy of the intervention.

The Review board and the NIH will be updated about the intervention, as soon as the investigators have decided what intervention is appropriate

Study Timeline

• Study Start: 2012-12
• Study First Submitted: 2012-12-02
• Study First Submitted QC: 2012-12-04
• Study First Posted: 2012-12-05
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-30
• Last Update Posted: 2016-08-31

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• All patients hospitalized with community acquired pneumonia treated by azythromycin

Exclusion Criteria

• Age under 18

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Before, After	education	The intervention is educational

Primary Outcome Measures

Name	Time	Method
length of intravenous azythromycin treatment	6 months

Trial Locations

Locations (1)

Haemek Medical Center; 🇮🇱 Afula, Israel